Radiofrequency renal denervation safe, effective in largest US trial

Medtronic's Symplicity Spyral device showed significant blood pressure reductions in the SPIRAL AFFIRM study, meeting its 6-month primary endpoint. The study, involving 594 patients, reported an 18.2 mm Hg reduction in office systolic BP, exceeding the 6 mm Hg performance goal. The results were consistent across various subgroups and showed minimal adverse events, according to data presented at TCT 2026.

Original reporting
Published Nov 17, 2026, 5:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 5:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Radiofrequency renal denervation safe, effective in largest US trial — source image
Decision brief

The 30-second read

$MDTBullishMed
01

Why it matters

SPIRAL AFFIRM presented at TCT 2026 reports a statistically significant 6-month office systolic BP reduction of 18.2 mm Hg versus a prespecified 6 mm Hg performance goal, with no increase in antihypertensive medication burden and minimal adverse events through 6 months.

02

Market read

A large US trial readout that clears a prespecified BP performance goal can shift perceived clinical efficacy and safety risk for the device, influencing medtech adoption expectations.

03

What to watch

The article emphasizes office BP and secondary measures but does not detail longer-term durability beyond 6 months, adverse-event specifics, or how results translate into reimbursement and real-world procedure volumes.

Relevance 8/10Novelty 7/10Timing: data presented at TCT 2026, immediate sentiment impact for device adoption expectations

Background

Radiofrequency renal denervation using the Symplicity Spyral catheter was FDA-approved for adults with uncontrolled hypertension, despite a slim FDA advisory panel vote questioning risk-benefit balance.

Company-level read

Ticker impact

$MDTBullishMedium confidence
Context

Article names Medtronic’s Symplicity Spyral renal denervation catheter and reports SPIRAL AFFIRM results meeting the 6-month BP endpoint without medication escalation.

Expected impact

Likely positive sentiment for MDT as investors price improved evidence for renal denervation uptake and reimbursement discussions.

Evidence & confidence

The piece is a pivotal-style efficacy/safety dataset (nearly 600-patient US cohort) tied to the specific device brand, which can shift perceived clinical risk versus earlier advisory-panel skepticism.

Market effects

Strengthens the interventional hypertension treatment evidence base, which could lift sentiment across renal denervation and cardiovascular device peers.

Primarily US-focused endpoint cohort details may influence US payer and guideline discussions.

International multicenter design and subgroup consistency may support broader global adoption narratives.

Counterpoint

FDA advisory panel previously voted that benefits did not outweigh risks; trial success may not fully resolve regulatory or payer skepticism, especially if endpoints or comparators are scrutinized.

Key entities

  • Medtronic

    Symplicity Spyral renal denervation catheter manufacturer referenced in the article.

  • Symplicity Spyral

    Radiofrequency renal denervation catheter used in the SPIRAL AFFIRM study.

  • SPIRAL AFFIRM

    Largest US cohort trial presented at TCT 2026 with a 6-month primary endpoint.

  • FDA advisory panel

    Previously voted by slim majority that benefits did not outweigh risks.

Related articles

$MDTMed

What Piper Sandler Sees Ahead for Medtronic (MDT)

Piper Sandler upgraded Medtronic (MDT) to Overweight, raising its price target to $120 from $85. The analyst expects revenue growth driven by cardiac ablation and other products. Medtronic's Q1 2027 sales showed strong growth, and it announced acquisitions and FDA clearances. The Fed is expected to raise rates in December, impacting Treasury yields and mortgage rates.